

New Hampshire Medicaid Fee-for-Service Program Prior Authorization Drug Approval Form

Niemann-Pick Disease Type C

DATE OF MEDICATION REQUEST: / /

SECTION I: PATIENT INFORMATION AND MEDICATION REQUESTED																								
LAST NAME:								FIRST NAME:																
MEDICAID ID NUMBER:									DATE OF BIRTH:															
												_] _									
GE	NDER	:		M	ale			Fei	male						I			J			<u>I</u>		_	
Drug Name:									Strength:															
Dosing Directions: Length of Therapy:																								
SECTION II: PRESCRIBER INFORMATION																								
LAST NAME: FIRST N						ST NAME:																		
SP	SPECIALTY: NPI NUMBER:																							
PHONE NUMBER: FAX NUMBER:																								
			_				_] _				_				
SECTION III: CLINICAL HISTORY																								
1.	1. Is the prescriber a geneticist or specialist in Niemann-Pick Disease Type C or has one been Yes No consulted?																							
2.	Does the patient have a diagnosis of Niemann-Pick Disease Type C?								No															
	If yes, was this confirmed with genetic analysis demonstrating mutation in NPC1 or NPC2 gene?								Yes No															
3.	3. Is the patient experiencing disease-related neurological symptoms?									Yes No														
	Please describe:																							
4.	Aqneursa: Provide the patient's current weight in kg.																							
5. Miplyffa: Will the patient be using miglustat concurrently?										Yes		No												

© 2025 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company

Review Date: 06/05/2025





New Hampshire Medicaid Fee-for-Service Program Prior Authorization Drug Approval Form

Niemann-Pick Disease Type C

DATE OF MEDICATION REQUEST: / /

	, , ,								
RENEWAL:									
1.	Has the patient experienced any treatment-restricting adverse effects?	Yes No							
2.	Has the patient benefited from the medication?	Yes No							
I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.									
PR	ESCRIBER'S SIGNATURE:	DATE:							

© 2025 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company

Review Date: 06/05/2025

